AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
In the realm of healthcare stocks, AbbVie and Johnson & Johnson are often compared, each presenting distinct advantages and risks. AbbVie is a specialized biopharmaceutical company, concentrating its efforts on immunology, oncology, and aesthetics. Its reliance on three key distributors, McKesson Corp, Cardinal Health Inc, and Cencora Inc, for nearly all U.S. sales, introduces a level of vulnerability; any disruption from a single partner could affect its distribution.
In contrast, Johnson & Johnson operates a more diversified medical conglomerate, having separated from its consumer health division. This broader business model offers stability, making it an attractive option for investors seeking reliable dividends and broader exposure to the healthcare sector.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
